Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference

MT Newswires Live

12/03

Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.

In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.

Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.

Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2588706497"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588706497\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588706497?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 06:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588706497","market":"sg","top_or_hot":-1,"title":"Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference","media":"MT Newswires Live","content":"<html><body><p> Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.</p><p>In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.</p><p>Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.</p><p>Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-03 06:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.</p><p>In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.</p><p>Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.</p><p>Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588706497","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588706497","pubTimestamp":1764716292,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen  and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BIIB":"渤健公司","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Biogen和卫材在2025年阿尔茨海默病临床试验会议上展示新的LEQEMBI生物标志物数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen (BIIB) and Eisai announced Tuesday that new data presented at the Clinical Trials on Alzheimer's Disease 2025 conference showed LEQEMBI produced measurable changes in levels of A-beta protofibrils in cerebrospinal fluid in a Phase 3 sub-study, Eisai said Tuesday.In the 410-patient cohort, Eisai said total protofibril levels increased more in the LEQEMBI group than in placebo at 12 and 18 months, with a statistically significant difference at 12 months. Eisai and Biogen said the results confirm that LEQEMBI binding to protofibrils can be measured in cerebrospinal fluid.Eisai said correlations seen in the placebo group between protofibril changes and several neurodegeneration and tau biomarkers were not observed with LEQEMBI treatment.Eisai leads development and regulatory submissions for LEQEMBI globally, and the companies co-commercialize the drug.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}